<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JAMA Dermatol</journal-id>
<journal-id journal-id-type="iso-abbrev">JAMA Dermatol</journal-id>
<journal-id journal-id-type="pmc">JAMA Dermatol</journal-id>
<journal-title-group>
<journal-title>JAMA Dermatology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2168-6068</issn>
<issn pub-type="epub">2168-6084</issn>
<publisher>
<publisher-name>American Medical Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29049491</article-id>
<article-id pub-id-type="pmc">5817460</article-id>
<article-id pub-id-type="doi">10.1001/jamadermatol.2017.3959</article-id>
<article-id pub-id-type="publisher-id">dbr170021</article-id>
<article-categories>
<subj-group specific-use="electronic" subj-group-type="category">
<subject>Research</subject>
</subj-group>
<subj-group specific-use="print" subj-group-type="domain">
<subject>Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Brief Report</subject>
</subj-group>
<subj-group subj-group-type="online-first">
<subject>Online First</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome</article-title>
<alt-title alt-title-type="headline">Dermal Hyperneury and Multiple Sclerotic Fibromas in MEN 2A Syndrome</alt-title>
<alt-title alt-title-type="running-head">Dermal Hyperneury and Multiple Sclerotic Fibromas in MEN 2A Syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Alegría-Landa</surname>
<given-names>Victoria</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="dbr170021aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jo-Velasco</surname>
<given-names>Margarita</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="dbr170021aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robledo</surname>
<given-names>Mercedes</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="dbr170021aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Requena</surname>
<given-names>Luis</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="dbr170021aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="dbr170021aff1"><label>1</label>Department of Dermatology, Fundación Jiménez Diaz, Universidad Autónoma, Madrid, Spain</aff>
<aff id="dbr170021aff2"><label>2</label>Department of Pathology, Fundación Jiménez Diaz, Universidad Autónoma, Madrid, Spain</aff>
<aff id="dbr170021aff3"><label>3</label>Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain</aff>
<author-notes>
<title>Article Information</title>
<corresp id="dbr170021cor1"><bold>Corresponding Author:</bold> Luis Requena, MD, Department of Dermatology, Fundación Jiménez Díaz, Avenida Reyes Católicos 2, 28040, Madrid, Spain (<email xlink:href="lrequena@fjd.es">lrequena@fjd.es</email>).</corresp>
<p><bold>Accepted for Publication:</bold> August 11, 2017.</p>
<p content-type="published-online"><bold>Published Online:</bold> October 18, 2017. doi:<uri content-type="doi">10.1001/jamadermatol.2017.3959</uri></p>
<p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Alegría-Landa and Requena had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
<p><italic>Study concept and design:</italic> Alegría-Landa, Jo-Velasco, Requena.</p>
<p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
<p><italic>Drafting of the manuscript:</italic> Alegría-Landa, Jo-Velasco, Requena.</p>
<p><italic>Critical revision of the manuscript for important intellectual content:</italic> All authors.</p>
<p><italic>Administrative, technical, or material support:</italic> Robledo.</p>
<p><italic>Study supervision:</italic> Alegría-Landa, Jo-Velasco, Requena.</p>
<p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p>
<p><bold>Additional Contributions:</bold> We thank the patient and her family for granting permission to publish this information.</p>
</author-notes>
<pub-date iso-8601-date="2017-10-18T10:00" pub-type="epub">
<day>18</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>10</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>153</volume>
<issue>12</issue>
<fpage></fpage>
<lpage></lpage>
<history>
<date date-type="received">
<day>18</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="final">
<day>5</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright 2017 American Medical Association. All Rights Reserved.</copyright-statement>
</permissions>
<self-uri content-type="pdf-version" xlink:href="jamadermatol-153-535.pdf">jamadermatol-153-535.pdf</self-uri>
<self-uri content-type="roundpoint" xlink:href="http://app.jamanetwork.com/?doi=10.1001/jamadermatol.2017.3959"></self-uri>
<self-uri content-type="silverchair" xlink:href="http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2017.3959"></self-uri>
<abstract abstract-type="teaser">
<p>This case report describes dermatologic similarities among family members with the familial medullary thyroid carcinoma variant of multiple endocrine neoplasia type 2A syndrome and cutaneous manifestations of multiple endocrine neoplasia type 2B and <italic>PTEN</italic> hamartoma-tumor syndromes.</p>
</abstract>
<abstract abstract-type="key-points">
<title>Key Points</title>
<sec id="ab-dbr170021-1">
<title>Question</title>
<p>Is there a phenotypic association between the cutaneous manifestations of multiple endocrine neoplasia type 2A and <italic>PTEN</italic> (phosphatase and tensin homologue) hamartoma-tumor syndromes?</p>
</sec>
<sec id="ab-dbr170021-2">
<title>Findings</title>
<p>A kindred of 11 individuals with familial medullary thyroid carcinoma variant of multiple endocrine neoplasia type 2A syndrome showed a moderate risk <italic>RET</italic> p.Val804Met (protein valine at residue 804 replaced by methionine) genetic mutation. Two family members had dermal hyperneury lesions characteristically seen in multiple endocrine neoplasia type 2B syndrome; 1 family member also showed multiple sclerotic fibromas, a cutaneous manifestation previously described in <italic>PTEN</italic> hamartoma-tumor syndrome, but not in multiple endocrine neoplasia type 2A syndrome.</p>
</sec>
<sec id="ab-dbr170021-3">
<title>Meaning</title>
<p><italic>PTEN</italic> hamartoma-tumor and multiple endocrine neoplasia type 2 syndromes show considerable overlap in the signaling pathways regulated by <italic>PTEN</italic> and <italic>RET</italic> genes, respectively, which may explain the clinical overlap between the 2 syndromes.</p>
</sec>
</abstract>
<abstract>
<sec id="ab-dbr170021-4">
<title>Importance</title>
<p>Multiple endocrine neoplasia type 2 (MEN 2) syndrome is an autosomal dominant, hereditary cancer disorder caused by germline mutations in the <italic>RET</italic> (formerly <italic>MEN2A, MEN2B</italic>) proto-oncogene located on chromosomal band 10q11.21. Two distinct clinical forms have been described as the following phenotypes: multiple endocrine neoplasia type 2A (MEN 2A) and multiple endocrine neoplasia type 2B (MEN 2B) syndromes. The common and necessary nexus that defines these 2 phenotypes is the presence of medullary thyroid carcinoma (MTC). The familial MTC type of MEN 2 syndrome was included within the spectrum of MEN 2A syndrome. Cutaneous manifestations of MEN 2A syndrome include macular amyloidosis, whereas MEN 2B syndrome is traditionally linked to multiple mucosal neuromas.</p>
</sec>
<sec id="ab-dbr170021-5">
<title>Objectives</title>
<p>To describe a family with cutaneous manifestations not previously described in patients with MEN 2A syndrome and to discuss the association of this disorder with Cowden syndrome.</p>
</sec>
<sec id="ab-dbr170021-6">
<title>Design, Setting, and Participants</title>
<p>Clinicopathologic correlation of cutaneous lesions and genetic studies in 11 members of a family with familial MTC.</p>
</sec>
<sec id="ab-dbr170021-7">
<title>Interventions</title>
<p>Cutaneous lesions were histopathologically and immunohistochemically studied. Genetic screening for a germline mutation at the <italic>RET</italic> gene was performed in 11 family members.</p>
</sec>
<sec id="ab-dbr170021-8">
<title>Main Outcomes and Measures</title>
<p>Identification of cutaneous lesions not previously described in patients with MEN 2A syndrome.</p>
</sec>
<sec id="ab-dbr170021-9">
<title>Results</title>
<p>This family of 11 individuals with familial MTC type of MEN 2A syndrome demonstrated the moderate risk <italic>RET</italic> p.Val804Met (protein valine at residue 804 replaced by methionine) genetic mutation, with 2 of the relatives presenting with dermal hyperneury, cutaneous lesions classically described in MEN 2B syndrome, and 1 relative also showing multiple sclerotic fibromas, a cutaneous manifestation of <italic>PTEN</italic> (phosphatase and tensin homologue) hamartoma-tumor syndrome.</p>
</sec>
<sec id="ab-dbr170021-10">
<title>Conclusions and Relevance</title>
<p>Dermal hyperneury and multiple sclerotic fibromas should be added to the list of cutaneous manifestations of patients with the familial MTC type of MEN 2A syndrome.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>